<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04145856</url>
  </required_header>
  <id_info>
    <org_study_id>HJM 0492/18-R</org_study_id>
    <nct_id>NCT04145856</nct_id>
  </id_info>
  <brief_title>Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico</brief_title>
  <official_title>Efficacy of the Combination Therapy With Alverine-simeticone and i3.1 Probiotic Formula in the Quality of Life of Patients With IBS-D or IBS-M in Hospital Juarez Mexico</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Juarez de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Juarez de Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized study evaluates the usefulness of the I31 probiotic formula, alone or in
      combination with alverine/simethicone, against placebo, in the treatment of
      diarrhea-predominant or mixed irritable bowel syndrome
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Irritable Bowel Syndrome (IBS) is a functional gastrointestinal disease in which recurrent
      abdominal pain is associated with defecation or a change in bowel habits. Disordered bowel
      habits are typically present (ie, constipation, diarrhea, or a mix of constipation and
      diarrhea), as are symptoms of abdominal bloating/distention.

      I31 is a probiotic formula composed of strains Pediococcus acidilactici CECT7483 and
      Lactobacillus plantarum CECT7484 and CECT7485, previously shown to improve quality of life in
      patients with IBS of Caucasian descent.

      Alverine/simethicone is a combination of two drugs: Alverine citrate relaxes muscle cramps
      that occur in the intestine in conditions such as irritable bowel syndrome and
      diverticulosis. Simethicone is an antifoam administered orally. Reduces gas formation and
      facilitates its elimination from the digestive tract
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 3, 2018</start_date>
  <completion_date type="Actual">August 27, 2019</completion_date>
  <primary_completion_date type="Actual">May 2, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-specific quality of life (QoL)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Irritable bowel syndrome-specific validated IBSQoL questionnaire (Hahn et al. Aliment Pharmacol Ther 1997). Response is defined as an improvement of 15 or more points in the normalized 0-100 score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Abdominal Pain</measure>
    <time_frame>6 weeks</time_frame>
    <description>Abdominal Pain Visual Analog Scale, ranging 0 to 10 (i.e. 11-point scale, as recommended by FDA, May 2012 Guidance on Irritable Bowel Syndrome - Clinical Evaluation of Products for Treatment). Response is defined as an improvement of 30% at the end of the intervention compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diarrhea</measure>
    <time_frame>6 weeks</time_frame>
    <description>Stool consistency as determined with the Bristol scale (Lewis &amp; Heaton, Scand. J. Gastroenterol 1997). Response is defined as a score equal or below 5 at the end of the intervention.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>- Control arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- Arm with active probiotic alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic + Antispasmodic/Antifoam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- Arm with active probiotic combined to antispasmodic/antifoam drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>I31 probiotic</intervention_name>
    <description>I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>I31 probiotic combined to Alverine/Simethicone</intervention_name>
    <description>I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)
Antispasmodic/antifoam drug, consisting of Alverine Citrate 60 mg and Simethicone 300 mg, thrice daily (t.i.d)</description>
    <arm_group_label>Probiotic + Antispasmodic/Antifoam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo treatment (maltodextrin), once daily (u.i.d)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects attending Hospital Juarez de Mexico with a diagnosis of diarrhea-predominant
             or mixed irritable bowel syndrome (IBS-D and IBS-M), according to Rome-IV criteria
             (Lacy et al. Gastroenterology 2016), providing Informed Consent.

        Exclusion Criteria:

          -  Unexplained weight loss, blood in feces, anemia.

          -  Use of systemic antibiotics, NSAIDs, antipsychotic or prokinetic medication in the 3
             weeks before study initiation.

          -  Pregnant or lactating women.

          -  History of gastrointestinal cancer.

          -  Suspicion of coeliac disease, inflammatory bowel disease (IBD), endometriosis or
             pelvic inflammatory disease.

          -  History of abdominal surgery within 2 years (3 months if appendectomy or herniorraphy)

          -  BMI below 18

          -  Known allergy to any of the components in the treatments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nuria Lopez Perez, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Juarez de Mexico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Juarez de Mexico</name>
      <address>
        <city>Ciudad de Mexico</city>
        <state>Cdmx</state>
        <zip>07760</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Juarez de Mexico</investigator_affiliation>
    <investigator_full_name>Nuria Pérez López</investigator_full_name>
    <investigator_title>Digestive Physiology Lab Head</investigator_title>
  </responsible_party>
  <keyword>Probiotic</keyword>
  <keyword>Antispasmodic</keyword>
  <keyword>Rome-IV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simethicone</mesh_term>
    <mesh_term>Alverine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

